Would you consider a treatment break for a patient with metastatic urothelial carcinoma who achieved a near-complete response to Enfortumab?  

The answer to this question is highly dependent on the specific clinical context. However, for a patient who has a deep and durable response to enfortumab vedotin monotherapy and has been on treatment for a prolonged period of time (again context dependent, but at least a few months), I think it is ...